First Participant Screening in A Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Therapy in U.S. Military Veterans with Chronic PTSD

MAPS is sponsoring a Phase 2, open-label protocol to study the comparative effectiveness of two vs. three MDMA-assisted therapy sessions in Veterans with PTSD at the James J. Peters Veterans Affairs (VA) Medical Center in Bronx, New York. The study site researchers are currently working through the screening assessments for the first participant with projected enrollment by the end of December 2021. The study will continue screening and enrollment after the first participant is fully enrolled. The study is expected to treat up to 60 participants over 2-3 years.